Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.

Bob T. Li,Ronglai Shen,Michael Offin,Darren J. Buonocore,Mackenzie L. Myers,Aishwarya Venkatesh,Pedram Razavi,Michelle S. Ginsberg,Gary A. Ulaner,David B. Solit,David M. Hyman,Charles M. Rudin,Erika Gedvilaite,Dana Tsui,Maria E. Arcila,Mark G. Kris,Gregory Weitsman,Tony Ng,Maurizio Scaltriti,Alan Loh Ho

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.

2019

6001Background: SGCs are rare tumors with no approved therapy for metastatic disease. HER2 amplification occurs in 8% among all SGC histologies, and 25-33% of the aggressive salivary duct carcinoma...

Keywords:

Salivary gland
Ado-trastuzumab emtansine
Pathology
Oncology
Internal medicine
Medicine
Disease
in patient
Salivary duct carcinoma
HER2 Amplification

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations